{"id":"NCT00221195","sponsor":"Tulane University School of Medicine","briefTitle":"Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors","officialTitle":"A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2003-06","primaryCompletion":"2009-12","completion":"2010-07","firstPosted":"2005-09-22","resultsPosted":"2017-02-06","lastUpdate":"2020-03-02"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hemophilia A With Inhibitors"],"interventions":[{"type":"DRUG","name":"activated prothrombin complex concentrate (FEIBA)","otherNames":[]}],"arms":[{"label":"On-demand first","type":"OTHER"},{"label":"Prophylaxis first","type":"OTHER"}],"summary":"The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.","primaryOutcome":{"measure":"Number of Bleeds During 6 Month Treatment Period","timeFrame":"6 months","effectByArm":[{"arm":"Bleeds During the On-demand Period","deltaMin":13.1,"sd":7.1},{"arm":"Bleeds During the Prophylaxis Period","deltaMin":5,"sd":5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"24 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23731246","22047559"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["Pyrexia","Ecchymosis","Influenza","Pain","Cough"]}}